Page 65 - GPD-2-4

Gene & Protein in Disease

ORIGINAL RESEARCH ARTICLE
Continuous topical application of

microencapsulated recombinant human
epidermal growth factor does not promote the

progression of established melanoma in animals

7
Chien-Shan Wu 1,2† , Jian-Ching Wu 3,4† , Ching-Min Tseng , Le-Shin Chang ,
5,6
8
Chi-Fang Wu , Yi-Tzu Li , Yi-Wen Lin , and Ming-Hong Tai 3,4,8 *
8
8
1 Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic
of China
2 Department of Dermatology, Pingtung Veterans General Hospital, Pingtung, Taiwan, Republic of
China
3 Doctoral Degree Program in Marine Biotechnology, National Sun Yat-sen University, Kaohsiung,
Taiwan, Republic of China
4 Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei, Taiwan, Republic of
China
5 Division of Chest Medicine, Department of Internal Medicine, Cheng Hsin General Hospital, Taipei,
Taiwan, Republic of China
6 School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taiwan,
Republic of China
7 College of Life Sciences, National Chung Hsing University, Taichung, Taiwan, Republic of China
8 Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan, Republic
† These authors contribute equally to of China
this work.
*Corresponding author:
Ming-Hong Tai
(minghongtai@gmail.com) Abstract
Citation: Wu C, Wu, J, Tseng C,
et al., 2023, Continuous topical Microencapsulated epidermal growth factor (EGF) device has been applied topically
application of microencapsulated
recombinant human epidermal for the management of several types of wounds to accelerate wound healing and
growth factor does not promote prevent scar formation. However, it remains unclear whether such EGF device induced
the progression of established neoplastic transformation in the skin. In this study, we exploited a well-established
melanoma in animals. Gene Protein
Dis, 2(4): 1848. murine B16-F10 melanoma model, coupled with MTT viability and colony formation
https://doi.org/10.36922/gpd.1848 assays, to investigate the influence of microencapsulated recombinant EGF (Me-EGF;
®
Received: September 16, 2023 brand name NewEpi ) and its ingredients on the tumorigenicity of skin cancer cells
Accepted: December 20, 2023 in vitro and in vivo. The results indicated that Me-EGF did not stimulate the viability
Published Online: December 29, nor the anchorage-dependent growth of B16-F10 melanoma cells. Western blot
2023 analysis showed that Me-EGF treatment increased the total and phosphorylated
Copyright: © 2023 Author(s). EGFR expression without affecting the HER2 expression in B16-F10 melanoma
This is an Open-Access article cells. In mice bearing established B16-F10 melanoma, continuous application of
distributed under the terms of the
Creative Commons Attribution Me-EGF for 14 days did not enhance the melanoma tumor burden compared with
License, permitting distribution, control groups. Immunohistochemical analysis also revealed the similar expression
and reproduction in any medium, of proliferative index Ki-67 between Me-EGF-treated melanoma and other groups.
provided the original work is
properly cited. Altogether, these results suggest that the application of Me-EGF device did not
promote the oncogenic potential of B16-F10 melanoma in vitro and in vivo.
Publisher’s Note: AccScience
Publishing remains neutral with
regard to jurisdictional claims in
published maps and institutional Keywords: Melanoma; Epidermal growth factor; Microencapsulation; Me-EGF
affiliations.

Volume 2 Issue 4 (2023) 1 https://doi.org/10.36922/gpd.1848